Clopidogrel

Drugs

Volumn 54, Issue 5, 1997, Pages 745-750

  Coukell, Allan J ^a   Markham, Anthony ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 CHLOROPHENYL) 2 (4,5,6,7 TETRAHYDROTHIENO[3,2 C]PYRIDIN 5 YL)ACETIC ACID; ACETYLSALICYLIC ACID; ADENYLATE CYCLASE; CARBOXYLIC ACID DERIVATIVE; CLOPIDOGREL; DIGOXIN; DRUG METABOLITE; THROMBOCYTE RECEPTOR; TICLOPIDINE; UNCLASSIFIED DRUG;

ARTERY THROMBOSIS; ATHEROSCLEROSIS; CLINICAL TRIAL; DIARRHEA; DIGOXIN BLOOD LEVEL; DRUG ABSORPTION; DRUG ACTIVATION; DRUG EFFICACY; DRUG METABOLISM; DRUG RECEPTOR BINDING; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEART MUSCLE ISCHEMIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER DISEASE; LIVER METABOLISM; NEUTROPENIA; NONHUMAN; ORAL DRUG ADMINISTRATION; RASH; REVIEW; STROKE; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE MEMBRANE; THROMBOCYTOPENIA; VASCULAR DISEASE; VEIN THROMBOSIS;

ANIMALIA;

EID: 0030724790     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199754050-00006     Document Type: Review

References (26)

1. Schrör K. Antiplatelet drugs: a comparative review. Drugs 1995 Jul; 50: 7-28
2. Herbert J-M. Clopidogrel and antiplatelet therapy. Expert Opin Invest Drug 1994 May; 3: 449-55
3. Savi P, Herbert JM, Pflieger AM, et al. Importance of hepatic metabolim in the antiaggregating activity of the thienopyridine clopidogrel. Biochem Pharmacol 1992; 44: 527-32
4. Herbert JM, Frehel D, Vallee E, et al. Clopidogrel. a novel antiplatelet and antithrombotic agent. Cardiovasc Drug Rev 1993; 11 (2): 180-98.
5. Gachet C, Stierle A, Cazenave J-P, et al. The thienopyridine PCR 4099 selectively inhibits ADP-induced platelet aggregation and fibrinogen binding without modifying the membrane glycoprotein IIb-IIIa complex in rat and in man. Biochem Pharmacol 1990 Jul 15; 40: 229-38
6. Mills DCB, Puri R, Hu C-J, et al. Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase. Arterioscler Thromb 1992 Apr; 12: 430-6
7. 3H]-2-methylthio ADP to rat platelets - effect of clopidoprel and ticlopidine. J Pharmacol Exp Ther 1994 May: 269: 772-7
8. Herbert JM, Tissinier A, Defreyn G, et al. Inhibitory effect of clopidogrel on platelet adhesion and intimal proliferation after arterial injury in rabbits. Arterioscler Thromb 1993; 13: 1171-9
9. Roald HE, Barstad RM, Kierulf P, et al. Clopidogrel - a platelet inhibitor which inhibits thrombogenesis in non-anticoagalated human blood independently of the blood How conditions. Thromb Haemost 1994 May; 71: 655-62
10. Bernat A, Mares AM, Defreyn G, et al. Effect of various antiplatelet agents on acute arterial thrombosis in the rat. Thromb Haemost 1993; 70: 812-6
11. Herbert JM, Bernat A, Maffrand JP. Importance of platelets in experimental venous thrombosis in the rat. Blood 1992 Nov 1; 80: 2281-6
12. Yao S-K, McNatt J, Anderson HV, et al. Concomitant administration of clopidogrel with tissue-type plasminogen activator delays reocclusion after thrombolysis in canine coronary arteries [abstract]. Circulation 1990 Oct; 82 Suppl. 3: 770
13. Caplain H, Kieffer G, Thiereelin JF, et al. Tolerance and clinical pharmacology of repeated administration of clopidogrel (SR 25990 C) a new antiplatelet agent, at three dose levels in normal healthy volunteers [abstract 1307]. Thromb Haemost 1989; 62 (1): 410
14. Bachmann E, Savcic M, Hauert J, et al. Rapid onset of inhibition of ADP-induced platelet aggregation by a loading dose of clopidogrel [abstract]. Eur Heart J 1996 Aug; 17 Abstract Suppl.: 263
15. Boneu B, Destelle G. Platelet anti-aggregating activity and tolerance of clopidogrel in atherosclerotic patients. Thromb Haemost 1996 Dec; 76: 939-43
16. Caplain H, D'Honneur G, Cariou R. Clinical tolerance and pharmacological activity of long term administration of clopidogrel in young healthy volunteers (abstract). J Clin Pharmacol 1996 Sep: 36: 861
17. Caplain H, D'Honneur G, Cariou R. Lack of interaction of aspirin (1000mg) with chronic clopidogrel in volunteers [abstract 557]. Haemostasis 1996; 26 Suppl. 3
18. D'Honneur G, Caplain H, Cariou R, et al. Interaction study between clopidogrel and prolonged intravenous heparin administration in young healthy volunteers [abstract no. 554]. Haemostasis 1996; 26 Suppl. 3
19. Forbes CD, Belch JJF, Bridges AB, et al. Pharmacodynamic compatibility of clopidogrel with atenolol and nifedipine comedication in patients with atherosclerotic disease [abstract]. Eur Heart J 1996 Aug; 17 Abstract Suppl.: 160
20. Savi P, Combalbert J, Gaich C, et al. The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A. Thromb Haemost 1994 Aug; 72: 313-7
21. Pierce CH, Houle J-M, Kieffer G, et al. Absence of effect of elopidogrel on human hepatic P-450 activities [abstract]. Eur Heart J 1996 Aug; 17 Abstract Suppl.: 160
22. Guillin M-C, Bonnet G, Sissmann J, et al. Pharmacodynamics and pharmacokinetics of the novel anti-platelet agent, clopidogrel, in the young and the elderly with and without symptomatic atherosclerosis [abstract]. Eur Heart J 1996 Aug; 17 Abstract Suppl.: 161
23. Peeters PAM, Crijns HJMJ, Tamminga WJ, et al. Absence of pharmacokinetic interaction between the novel antiplatelet agent, clopidogrel, and digoxin [abstract]. Eur Heart J 1996 Aug; 17 Abstract Suppl.: 160
24. McEwen J, Strauch G, Perles P, et al. Clopidogrel bioavailability is unaffected by food or antacids [abstract]. J Clin Pharmacol 1996 Sep; 36: 856
25. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996 Nov 16; 348: 1329-39
26. Gent M, Roberts RS. CAPRIE Investigators. Benefit of clopidogrel in patients with coronary disease [abstract]. Can J Cardiol 1997 Aug; In press